{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:09:07Z","timestamp":1777860547672,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Beh\u00e7et\u2019s disease (BD) is associated with an increased risk of cancer. Few reports have been published on the relationship between drug exposure and the risk of cancer in patients with BD. Herein, we explored the relationship between pharmacologic interventions for BD and the risk of cancer.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> we carried out a retrospective nested case-control study in a cohort of BD patients from attending our institution. Among 1,148 patients, 22 cancer patients were individually 1:2 matched to 44 cancer-free controls. The following biochemical indicators were evaluated: routine blood analysis, liver and kidney function tests, inflammatory indexes, blood gas analysis, blood electrolyte and previous pharmacologic interventions to manage BD including systemic glucocorticoids, methotrexate, cyclosporine-A, azathioprine, cyclophosphamide (CYC), and thalidomide, which are considered the primary medicines used for the management of BD.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among the 22 BD patients with cancers, myelodysplastic syndrome (MDS) (22.72%) was the most common type. Furthermore, CYC administration was significantly higher in BD patients with cancer compared with the cancer-free matched control group. Further, we observed that complement 4 (C4) (odds ratio [OR] = 0.0001, 95% confidence interval [CI]: 0.001\u20130.065) and hemoglobin (Hb) (OR = 0.891, 95% CI: 0.795\u20130.998) levels were independent protective factors for predicting cancer risk in BD patients on multivariate analyses.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study revealed that CYC was associated with a high risk of cancer in BD patients. Furthermore, C4 and Hb are independent protective factors for oncogenesis in BD patients. These findings may provide references and suggestions for clinicians to select appropriate treatments and for the early recognition of high-risk patients to reduce cancer incidence in BD patients.<\/jats:p>","DOI":"10.3389\/fphar.2021.661150","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T06:46:26Z","timestamp":1626763586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacotherapy for Beh\u00e7et\u2019s Disease and the Risk of Malignancy"],"prefix":"10.3389","volume":"12","author":[{"given":"Mao-Xin","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-An","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00296-009-1319-3","article-title":"Behcet's Disease Associated with Malignancy in Korea: a Single center Experience","volume":"30","author":"Ahn","year":"2010","journal-title":"Rheumatol. Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11940-011-0120-2","article-title":"Beh\u00e7et's Disease","volume":"13","author":"Akman-Demir","year":"2011","journal-title":"Curr. Treat. Options. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The Evolution of Thalidomide and its IMiD Derivatives as Anticancer Agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/cjn.08880813","article-title":"Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy","volume":"9","author":"Brand","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using Cyclophosphamide in Inflammatory Rheumatic Diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"172421","DOI":"10.1016\/j.ejphar.2019.172421","article-title":"The Involvement of DAMPs-Mediated Inflammation in Cyclophosphamide-Induced Liver Injury and the protection of Liquiritigenin and Liquiritin","volume":"856","author":"Chen","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and Cancer: Advances and New Agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","article-title":"Behcet's Disease: Epidemiology, Clinical Manifestations, and Diagnosis","volume":"13","author":"Davatchi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged Risk of Specific Malignancies Following Cyclophosphamide Therapy Among Patients with Granulomatosis with Polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/s0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long Term Follow-Up of Beh\u00e7et's Syndrome Patients Treated with Cyclophosphamide","volume":"59","author":"Gurcan","year":"2020","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0268-960x(92)90028-o","article-title":"Mechanisms of Action of, and Modes of Resistance to, Alkylating Agents Used in the Treatment of Haematological Malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5009\/gnl17324","article-title":"Cancer Risk in Patients with Intestinal Beh\u00e7et's Disease: A Nationwide Population-Based Study","volume":"12","author":"Han","year":"2018","journal-title":"Gut Liver"},{"key":"B16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 Update of the EULAR Recommendations for the Management of Beh\u00e7et's Syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s10067-020-05386-9","article-title":"Risk Factors of Disease Activity in Patients with Beh\u00e7et's Syndrome","volume":"40","author":"Hou","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1002\/art.38116","article-title":"Copy Number Variations of Complement Component C4 Are Associated with Beh\u00e7et's Disease but Not with Ankylosing Spondylitis Associated with Acute Anterior Uveitis","volume":"65","author":"Hou","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/carcin\/bgg083","article-title":"Roles of Keratinocyte Inflammation in Oral Cancer: Regulating the Prostaglandin E2, Interleukin-6 and TNF- Production of Oral Epithelial Cells by Areca Nut Extract and Arecoline","volume":"24","author":"Jeng","year":"2003","journal-title":"Carcinogenesis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jop.12004","article-title":"Thalidomide: Features and Potential Significance in Oral Precancerous Conditions and Oral Cancer","volume":"42","author":"Jin","year":"2013","journal-title":"J. Oral Pathol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0190182","DOI":"10.1371\/journal.pone.0190182","article-title":"Cancer Risk in Korean Patients with Beh\u00e7et's Disease: A Nationwide Population-Based Study","volume":"12","author":"Jung","year":"2017","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-\u03baB Activity by Thalidomide through Suppression of I\u03baB Kinase Activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1038\/sj.onc.1207230","article-title":"To Be, or Not to Be: NF-\u03baB Is the Answer - Role of Rel\/NF-\u03baB in the Regulation of Apoptosis","volume":"22","author":"Kucharczak","year":"2003","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/1756-185X.12269","article-title":"Behcet's Disease Associated with Malignancy: a Report of 41 Chinese Cases","volume":"17","author":"Lin","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/14740338.2020.1817379","article-title":"Safety of Systemic Treatments for Beh\u00e7et's Syndrome","volume":"19","author":"Lopalco","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.4049\/jimmunol.168.6.2644","article-title":"Thalidomide Suppresses NF-\u03baB Activation Induced by TNF and H2O2, but Not that Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester","volume":"168","author":"Majumdar","year":"2002","journal-title":"J. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","article-title":"Con: Cyclophosphamide for the Treatment of Lupus Nephritis","volume":"31","author":"Mok","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2017.09.035","article-title":"Cancer Risk in Patients with Beh\u00e7et Disease: A Nationwide Population-Based Dynamic Cohort Study from Korea","volume":"78","author":"Na","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide Selectively Inhibits Tumor Necrosis Factor Alpha Production by Stimulated Human Monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J. Exp. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.3748\/wjg.v20.i13.3516","article-title":"Hepatitis B and C Virus Reactivation in Immunosuppressed Patients with Inflammatory Bowel Disease","volume":"20","author":"Sansone","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.ejca.2004.07.023","article-title":"Thalidomide in Solid Tumours: the Resurrection of an Old Drug","volume":"40","author":"Sleijfer","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative Cancer Risk Associated with Methotrexate, Other Non-biologic and Biologic Disease-Modifying Anti-rheumatic Drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s1085-5629(98)80019-9","article-title":"Thalidomide and its Impact in Dermatology","volume":"17","author":"Stirling","year":"1998","journal-title":"Semin. Cutan. Med. Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/MOL.0000000000000314","article-title":"Effects of Melatonin on Cardiovascular Diseases","volume":"27","author":"Sun","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3899\/jrheum.140770","article-title":"Risk of Overall and Site-specific Cancers in Beh\u00e7et Disease: A Nationwide Population-Based Study in Taiwan","volume":"42","author":"Wang","year":"2015","journal-title":"J. Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e17735","DOI":"10.1097\/MD.0000000000017735","article-title":"Risk of Malignancy in Behcet Disease","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e18443","DOI":"10.1097\/MD.0000000000018443","article-title":"Diagnostic Value of Hemoglobin and Neutrophil-To-Lymphocyte Ratio in Behcet Disease","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.661150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T06:46:29Z","timestamp":1626763589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.661150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":37,"alternative-id":["10.3389\/fphar.2021.661150"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.661150","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"article-number":"661150"}}